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Background & aims: Polyphenol intake has been linked to improvements in human vascular function,
although data on hydroxycinnamates, such as chlorogenic acid (CGA) have not yet been studied. We
aimed to investigate the impact of coffee intake rich in chlorogenic acid on human vascular function and
whether CGAs are involved in potential effects.
Methods: Two acute randomized, controlled, cross-over human intervention trials were conducted. The
impact of coffee intake, matched for caffeine but differing in CGA content (89, and 310 mg) on ﬂow-
mediated dilatation (FMD) was assessed in 15 healthy male subjects. In a second intervention trial
conducted with 24 healthy male subjects, the impact of pure 5-caffeoylquinic acid (5-CQA), the main CGA
in coffee (5-CQA; 450 mg and 900 mg) on FMD was also investigated.
Results: We observed a bi-phasic FMD response after low and high polyphenol, (89 mg and 310 mg CGA)
intake, with increases at 1 (1.10 ± 0.43% and 1.34 ± 0.62%, respectively) and 5 (0.79% ± 0.32 and
1.52% ± 0.40, respectively) hours post coffee consumption. FMD responses to coffee intake was closely
paralleled by the appearance of CGA metabolites in plasma, notably 3-, 4- and 5-feruloylquinic acid and
ferulic-40-O-sulfate at 1 h and isoferulic-30-O-glucuronide and ferulic-40-O-sulfate at 5 h. Intervention
with puriﬁed 5-CQA (450 mg) also led to an improvement in FMD response relative to control
(0.75 ± 1.31% at 1 h post intervention, p ¼ 0.06) and concomitant appearance of plasma metabolites.
Conclusions: Coffee intake acutely improves human vascular function, an effect, in part, mediated by 5-
CQA and its physiological metabolites.
Study registration: The National Institutes of Health (NIH) on ClinicalTrials.gov NCT01813981 and
NCT01772784.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A, 3 feruloylquinic acid; 4-CQA, 4-caffeoylquinic acid; 4-CQ15L, 4-caffeoylquinic-1,5-lactone; 4-FQA, 4-feruloylquinic
caffeoylquinic acid; 5-FQA, 5-feruloylquinic acid; Ach, acetylcholine; ANOVA, analysis of variance; C3S, caffeic-30-O-
acid; CV, coefﬁcient of variance; CE, collision cell entrance potential; CPX, collision cell entrance potential; DP,
TA, ethylene-diamine-tetra-acetic acid; FA, ferulic acid; F4G, ferulic-40-O-glucuronide; F4S, ferulic-40-O-sulfate; FMD,
ein; HSD, highest signiﬁcant difference; HPC, high polyphenol coffee; IAUC, incremental area under the curve; iFA,
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C.E. Mills et al. / Clinical Nutrition 36 (2017) 1520e1529 15211. Introduction 2.2. SubjectsModerate coffee consumption (3e5 servings per day) has been
associated with reductions in both stroke and heart disease risk
[1,2], something that may be related to its high levels of phenolic
acids. A serving of coffee may contain between 27 and 121 mg of
phenolic acids (200 mL), most notably the hydroxycinnamate
chlorogenic acid (CGA), which is high in dietary terms [3]. Pre-
vious clinical trials indicate that the intake of phenolic-rich foods
such as berries [4], grape/wine [5], tea and cocoa [6], which all
contain structurally related phenolics, improve endothelium-
dependent vascular reactivity, suggesting coffee, may also be
capable of similar vascular beneﬁts. Despite this, controlled hu-
man intervention studies with coffee are few and most have
focused on the effects of caffeine, rather than that of the phenolics
present, yielding data ambiguous as the overall inﬂuence of
caffeine and/or coffee on vascular function [8e10]. However,
previous studies with CGA in both humans [11] and animals [12]
have indicated a potential for coffee to inﬂuence vascular end-
points, such as blood pressure, plasma cholesterol levels [13,14]
and ﬂow mediated dilatation (FMD), a measure of endothelial
dysfunction [15].
The CGA content of coffee is highly variable, depending to a
large degree on its processing into the ﬁnal consumed form,
particularly bean roasting, which is detrimental to CGA levels [16].
Thus, presently, it is unclear as to the levels of CGAs sufﬁcient to
induce physiological effects on the endothelium. Furthermore, the
impact of coffee intake on vascular function over prolonged pe-
riods is also unclear. Studies using coffee and pure chlorogenic acid
indicate that CGA absorption/metabolism may occur partly in the
small intestine and also in the large intestine [17,18], where the
microbiota activity cleaves the quinic acid moiety to yield caffeic
acid which may then undergo further metabolism and/or ab-
sorption in the large intestine [19]. This absorption proﬁle of CGA
in humans and the inherent differences in CGA content of differ-
ently processed coffees, provides an opportunity to investigate
whether CGA is linked to the vascular effects of coffee intake in
humans, via interactions of circulating CGA metabolites on the
vascular epithelium.
As such, the current investigations were designed to test the
hypothesis that CGA is causally related to improvements in
endothelial function, measured here as FMD, by conducting two
clinical trials: ﬁrstly a randomized, controlled, single blinded,
crossover intervention trial with two coffees differing in CGA
content and controlled against caffeine (efﬁcacy study); and a
second supporting doubled blinded intervention trial using pure
5-caffeoylquinic acid (5-CQA; the major CGA in coffee) isolated
from coffee (proof of concept study (POC)). Vascular measures are
linked to measures plasma CGA metabolites in order to build
cause-and-effect relationships between CGA intake, individual
vascular responses and circulating levels of CGA metabolites.2. Subjects and methods
2.1. Clinical trial ethics
Both clinical studies were conducted in line with the guide-
lines in the Declaration of Helsinki and study protocols were
approved by the University of Reading Research Ethics Commit-
tee, UK (reference: 11/31) and Kantonale Ethikkommission Bern,
Switzerland (reference 039/12). The trials were registered with
the National Institutes of Health (NIH) records on ClinicalTrials.
gov website (NCT01813981; efﬁcacy study, NCT01772784; POC
study).During year 2011,16 healthy male volunteers were recruited and
enrolled onto efﬁcacy study, a three arm, randomized, controlled,
sinlge-blinded, crossover clinical trial and in year 2012 24 male
volunteers were enrolled on POC study, a four arm, randomized,
double-blinded, crossover clinical trial; all volunteers gave written
informed consent prior to their participation (Fig. 1).
For both studies, volunteers were screened before to the start of
the trial to ensure they were in good health and were selected
according to the inclusion criteria in Table 1. Note, that using the
same inclusion criteria for POC study as for efﬁcacy study resulted in
some volunteers in this study having basal FMD values higher than
8.5%. As such, in order to maximize our chances of observing in-
creases in % FMD following CGA intake, we introduced an inclusion
criteria of moderate smoking in order to recruit a population with
basal % FMD at rest of between 5 and 6%. Those selected for the
study were asked not to change their usual dietary or ﬂuid intake
and asked to refrain from consumption of polyphenols rich foods
including fruits, vegetables, cocoa, chocolate, coffee, tea and wine,
all alcoholic beverages in addition to refraining from vigorous ex-
ercise such as running, swimming and other high aerobic forms of
exercise for 24 h prior to, and during, the study.
2.3. Interventions
For efﬁcacy study a low polyphenol soluble coffee (LPC): roasting
to internal bean temperature of 225 C), containing 89 mg CGA per
3.6 g of coffee and a high polyphenol coffee (HPC) derived from
combining 50% roasted and 50% green beans (165 C), containing
310 mg CGA (3.6 g ground coffee) were utilized. Both coffees were
prepared by addition of 3.6 g of ground coffee to 50 mL of hot
(90 C), nitrate/nitrite free water. The control intervention was
110 mg caffeine and 0 mg CGA in nitrate/nitrite free hot water,
whilst 28 mg of caffeine was added to LPC in order to match with
both the control and the HPC (efﬁcacy study) (Table 2).
For POC study 450 mg puriﬁed 5-CQAþ 1 g maltodextrin;
900 mg puriﬁed 5-CQAþ 1 g maltodextrin, doses of CGA shown to
decrease cardiovascular disearse risk [21]; 1 g maltodextrin
(negative control) and 200 mg puriﬁed ()-epicatechinþ 1 g
maltodextrin (positive control). Each treatment was reconstituted
in 200 mL of warm, nitrate/nitrite free water (~60 C) and stirred
until completely dissolved.
2.4. Study design
Both studieswere randomized controlled crossover trials. Efﬁcacy
study was 3 armed and single blinded (researcher blinded; partici-
pant not due to water control), where subjects consumed a LPC, a
HPC, or a caffeine control. The two intervention coffees were indis-
tinguishable in appearance and taste. POC study was 4 armed and
doubled blinded where volunteers consumed two doses of 5-CQA, a
negative and positive control; interventions were indistinguishable.
In both studiesparticipantswere assigned unique sequential random
numbers, which was previously allocated to one sequence of the
study products according to a computer generated paper list pro-
duced by a researcher not otherwise involved in the study. All study
personnel involved in the assessment of study outcomes, including
nurses, care providers, researchers and the principle investigator,
were blinded to intervention and intervention order.
On arrival at the Hugh Sinclair Unit for Human Nutrition, Uni-
versity of Reading, UK (efﬁcacy study) or Department of Cardiology
and Clinical Research, Inselspital, University Hospital Bern,
Switzerland, POC study, subjects were rested for 30 min in a quiet,
temperature controlled room (~21 C) before they were cannulated
Fig. 1. Flow diagram for study participation in clinical efﬁcacy study (A) and Clinical POC study (B).
Table 1
Inclusion and exclusion.
Efﬁcacy study POC study
Inclusion 18- 40 years 18-70 years
BMI 18e25 kg/m2 BMI 18e30 kg/m2 (and >55 kg)
Normal range liver enzymes, hemoglobin, hematocrit and
leukocyte counts
a
No diabetes or hypertension (>150/90 mm Hg) No diabetes, hypo or hypertension
(101/51e160/100 mm Hg)
Baseline ﬂow mediated dilatation <8.5% Baseline ﬂow mediated dilatation <8.5%
Smoking 5e10 cigarettes per day
Exclusion Being female Being female
Taking anti-inﬂammatory or antihypertensive medication or
antibiotics within two months
Taking any regular medication within two months
Participating in vigorous exercise (>3  30 min/week) Participating in vigorous exercise (>3  30 min/week)
Drinking > 168 g alcohol per week Drinking > 280 g alcohol per week
Smoking
BMI, body mass index; POC, proof of concept.
a Although not part of inclusion criteria, all participants had normal biochemistry results as tested at the ﬁrst visit.
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tional 10 min of rest, baseline FMD measurements of the brachial
artery (primary outcome), blood pressure and laser Doppler im-
aging with iontophoresis [20] to measure cutaneous perfusion of
acetylcholine and sodium nitroprusside; only measured in efﬁcacy
study (secondary outcomes). Following baseline measurements,
volunteers consumed one of the interventions within a 5 min or
2 min period (efﬁcacy and POC study respectively). FMD and blood
samples were acquired at 13, and 5 h for efﬁcacy study and 1 and 4 h
for POC study. Laser Doppler imaging was performed only in efﬁcacy
study at 1, 3 and 5 h peripheral BP measurements were performed
at 1, 3, and 5 h for efﬁcacy study and 0.5, 1, 2, 3 and 4 h for POC study,
post-consumption. Following the conclusion of each arm, volun-
teers undertook a 1-week washout period before switching to an
alternate study arm.2.5. Flow-mediated dilatation
FMD of the brachial artery was the primary end point measure
of the studies andwasmeasured following standard guidelines [22]
using an ALT Ultrasound HDI5000 system (ATL Ultrasound, UK),
with a semi-automated computerized analysis system (Brachial
Analyzer, Medical Imaging Applications-llc, IL, US) for Intervention
efﬁcacy study. An Esaote MyLab30 Gold, (Esaote SpA, Italy) with a
high frequency probe (7e10 MHz) linear array probe with edge
detection software with a system for real-time measurement of the
brachial artery diameter in B-mode ultrasound images (Cardio-
vascular Suite, Quipu, Pisa, Italy) was used for Intervention POC
study as previously described [23]. For both studies brieﬂy, after
30 min supine rest in a quiet, air-conditioned room, the brachial
artery was imaged longitudinally at 2e10 cm proximal to the
Table 2
Composition of intervention coffee and control drinks used in Clinical study I.
Caffeine control drink Low polyphenol coffee High polyphenol coffee
3-Caffeoylquinic acid (mg) 0 20 43
4-Caffeoylqunic acid (mg) 0 22 45
3-Feruloylquinic acid (mg) 0 4 10
5-Caffeoylqunic acid (mg) 0 29 124
4-Feruloylquinic acid (mg) 0 4 6
5-Feruloylquinic acid (mg) 0 5 24
3, 4-Dicaffeoylqunic acid (mg) 0 2 23
3, 5-Dicaffeoylqunic acid (mg) 0 1 17
4, 5-Dicaffeoylqunic acid (mg) 0 2 19
Caffeine (mg) 110 110 110
Energy (kcal)a 0 2.27 2.21
Protein (g)a 0 0.25 0.31
Carbohydrate (g)a 0 0.32 0.20
of which sugars (g)a 0 0.32 0.20
Fat (g)a 0 0.01 0.01
Fiber (g)a 0 0.97 1.08
Salt equivalent (g)a 0 0.01 0.01
Total chlorogenic acids (mg) 0 89 310
a As deﬁned on coffee label.
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which a blood pressure cuff placed around the forearmwas inﬂated
to 220 mm Hg or 250 mm Hg (for Intervention I and POC study
respectively). After 5 min of occlusion, the pressure was rapidly
released to allow reactive hyperemia, with image collection
continuing for 5 or 4 min (for Intervention I and POC study
respectively) post release. A single, fully trained researcher per
center, who was blinded to the intervention details, analyzed all
image ﬁles for the respective studies and peak diameter was
deﬁned as the maximum diameter obtained after the occlusionwas
released. FMD response was calculated as relative diameter change
from baseline as compared to peak diameter during hyperemia and
presented as percentage change.
2.6. Laser Doppler imaging
laser Doppler ﬂowmetry/imaging to measure cutaneous perfu-
sion accompanied by iontophoresis of acetylcholine and sodium
nitroprusside was carried out as previously described [24] and was
utilized in efﬁcacy study only (as a secondary outcome). Measure-
ments were taken after 30 min of acclimatization in a supine po-
sition in a quiet, temperature controlled room (22e24 C). The
incremental area under the ﬂux versus time curve for 20 scans was
used as a measure of micro vascular response to acetylcholine (Ach;
endothelium dependent vasodilation) and sodium nitroprusside
(SNP; endothelium independent vasodilation).
2.7. Systolic and diastolic blood pressure
SBP and DBP (also secondary outcomes) were measured in both
intervention studies after subjects had rested for 30 min in the
supine position using Omron MX2 (study 1) and Omron M6 (POC
study), both automatic digital upper-arm blood pressure monitor.
Blood pressure readings were taken every 2 min until 3 successful
readings were obtained. The average of these readings were
calculated and reported.
2.8. Plasma CGA/metabolite analysis
The blood samples were collected in EDTA treated tubes and
spun (1700  g; 10 min; 4 C) immediately after collection and
plasma was stored in 0.5 mL aliquots with antioxidant, ascorbic
acid, at 80 C. Sample preparation was performed at NestleResearch Centre, Laussanne, Switzerland according toMarmet et al.
[25]. Brieﬂy, in a 2 mL Eppendorf tube, 100 mL of plasma (stored
with EDTA/Vitamin C) spiked with 5 mL of internal standards (2 mM)
was vortexed, and mixed with 500 mL of ethanol for protein pre-
cipitation. After centrifugation at 17,500 g for 5 min at 4 C the
supernatant was transferred into a 1.5 mL Eppendorf tube and the
solvent was evaporated under nitrogen. The residue was extracted
one more time, the supernatants pooled and the solvent dried
again under nitrogen. After evaporation of the solvents, the residue
was then mixed with 100 mL of 1% acetic acid 5% acetonitrile
aqueous solution and injected (5 mL) for analysis by ultra perfor-
mance liquid chromatography electrospray ionization mass spec-
trometry (UPLC-ESI-MSn). CGA metabolites were separated by
reversed-phase UPLC using a C18-column Acquity UPLC BEH C18
1.7 mm, 2.1  150 mm, (Waters AG, Baden-D€attwil, Switzerland).
The system consists of an Nexera UPLC (Shimadzu Schweiz GmbH,
Reinach, Switzerland) connected to a Triple QUAD 5500 mass
spectrometer detector equipped with an electron spray ionisation
source (AB Sciex Switzerland GmbH, C/o Applied Biosystems
Europe BV, Zug, Switzerland). The molecular transitions listed in
Supplementary Table 1 were used to qualify and quantify phenolic
acids, their metabolites and the three internal standards (speciﬁc
analytical parameters are indicated for each compound). The cali-
bration curve was injected in singlet, but for all plasma samples,
duplicate analysis was performed. Data were collected and pro-
cessed using Analyst software (AB Sciex Switzerland GmbH, C/o
Applied Biosystems Europe BV, Zug, Switzerland). Each partici-
pants' samples were analyzed within a single assay batch in
random sequence. The samples were analyzed blind.2.9. Power calculation and statistical analysis
Power calculations were performed for the primary endpoint,
change in FMD response. In efﬁcacy study, power was based on the
intra-individual variability of the operator that performed the FMD
analysis (5% CV, SD ¼ 0.3, based on previous studies where the
same subjects weremeasured on 4 different days at the same time).
At 0.85 power and 0.05 signiﬁcance, the number of subjects
required to detect a difference of 1.5% FMD in the response of
matched pairs in a crossover study was 15. This number is consis-
tent with other studies carried out with similar endpoints and
study design [26,27]. Two-way repeated measures ANOVA were
ﬁtted to analyze the data using GraphPad Prism version 6
Fig. 2. % FMD (A) and plasma levels of total chlorogenic acid metabolites (sum of 56
identiﬁed) (B) following consumption of high polyphenol coffee ( ) and low poly-
phenol ( ) (containing 310 mg and 89 mg chlorogenic acid respectively) and a
caffeine matched control drink ( ) (n ¼ 15). Data were analyzed using two-way
repeated measures ANOVA with time and treatment as the two factors. Post hoc an-
alyses were conducted using a Tukey's HSD multiple comparisons test. Values pre-
sented are means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, signiﬁcantly different
respect to control drink at the speciﬁed time point.
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carried out using the Bonferroni test. In POC study, a sample size of
24 subjects was estimated to have a power >0.85 to detect a mean
difference of 1.5% FMD for the positive control considering a paired
t-test of a normal mean difference with a two-sided signiﬁcance
level of 0.05, assuming a common standard deviation of 3% and
correlation of at least 0.7. For all efﬁcacy (primary and secondary)
parameters, absolute changes from pre-dose (t0) were to be
analyzed according to a mixed model for cross-over design with
repeated measurements: the model was to include treatment,
period, sequence, time point and its interaction with treatment as
ﬁxed effects, and volunteer and its interaction with period as
random effects; change from pre-dose comparison between each of
the 2 active 5-CQA doses and the negative control at 1 h post dose
were to be derived from the model, and estimates and 95% conﬁ-
dence intervals (CI) for the differencewere to be provided as well as
nominal p-values. Signiﬁcance was deﬁned as p < 0.05, with p-
values represented in the ﬁgures as *p < 0.05, **p < 0.01,
***p < 0.001. The incremental area under the laser Doppler imaging
ﬂux versus time curve was calculated using the trapezoidal
method. Correlation analysis was performed using Pearson's cor-
relation coefﬁcient.
3. Results
3.1. Baseline anthropometry and intervention tolerance
The baseline characteristics of subjects enrolled in both studies
were all within normal limits (Table 3). All interventions were well
tolerated by all subjects and no adverse events were reported.
3.2. Coffee induced a biphasic increase in FMD
A biphasic increase in endothelium-dependent brachial artery
vasodilation, measured as % FMD, was observed in response to
consumption of both the HPC and LPC at 1 and 5 h, relative to the
caffeine control (Fig. 2, A). A signiﬁcant effect with respect to time
(p¼ 0.002) and highly signiﬁcant treatment effect (p < 0.0001) was
observed. Post-hoc analysis indicated that, at 1 h post intervention,
therewere highly signiﬁcant increases in % FMD in response to both
LPC (1.10 ± 0.43%; p < 0.05) and HPC (1.34 ± 0.62%; p < 0.05),
relative to a control change of 0.07 ± 0.06%. At 5 h, HPC signiﬁcantly
increased % FMD by 1.52 ± 0.40%) (p < 0.0001), whilst LPC increased
it by 0.79 ± 0.32%, (p < 0.05), relative to a control change
of 0.46 ± 0.38% (Fig. 2, A). The difference in % FMD increase
induced by the two doses of CGA, delivered as coffee, was not
signiﬁcant, although there was a trend for a differential increase %
FMD at 5 h (p < 0.1). Neither the LPC or the HPC induced signiﬁcant
changes in endothelium-independent (SNP; p > 0.05) or endothe-
lial dependent (acetyl choline; p > 0.05) micro-vascular blood ﬂow
(Ach) (Table 4). Similarly, there were no signiﬁcant changes inTable 3
Baseline clinical characteristics study population.a
Characteristic Efﬁcacy study POC study
N 15 24
Age (years) 26.3 ± 1.6 23.8 ± 1.4
BMI (kg/m2) 23.5 ± 0.5 23.2 ± 0.4
PSBP (mmHg) 124 ± 2.5 130.5 ± 2.0
PDBP (mmHg) 75 ± 2.3 76.9 ± 1.3
Brachial diameter (mm) 3.0 ± 0.2 3.7 ± 0.1
FMD (%) 5.7 ± 0.3 6.4 ± 0.3
BMI, body mass index; POC, proof of concept; PSBP, peripheral systolic blood
pressure; PDBP, peripheral diastolic blood pressure; FMD, ﬂow mediated dilatation.
a Results are expresses as mean ± SEM.either systolic or diastolic blood pressure in response to any of the
interventions (Tables 4 and 5).3.3. Plasma CGA metabolites
Similar to that observed with the FMD response, a biphasic in-
crease in total plasma CGA metabolites was observed, peaking at
1 h initially and increasing again 5 h post intervention (Fig. 2, B). A
signiﬁcant effect with respect to both time (p < 0.05) and treatment
(p < 0.001) were found for the total of the plasma CGAmetabolites.
HPC led to a signiﬁcant increase (p < 0.001) in total plasma CGA
metabolites 5 h after intake relative to the control. Despite
observing similar plasma CGA metabolite proﬁles in response to
LPC intake, these did not achieve signiﬁcance, although there was
also a trend to increase at 5 h, relative to the control.
Table 4
Acute effects of coffee on blood pressure and micro vascular dilation.a
Baseline 1 h 3 h 5 h
IAUC LDI SNP (PU.h¡1)3
HPC (236 mg CGA) 423 ± 153 424 ± 107 346 ± 75 431 ± 127
LPC (108 mg CGA) 541 ± 142 266 ± 75 501 ± 68 523 ± 125
Control (0 g CGA) 431 ± 132 250 ± 56 295 ± 71 262 ± 56
IAUC LDI Ach (PU.h¡1)
HPC (236 mg CGA) 272 ± 104 378 ± 64 300 ± 57 321 ± 84
LPC (108 mg CGA) 478 ± 147 237 ± 72 333 ± 63 288 ± 78
Control (0 g CGA) 387 ± 86 194 ± 53 222 ± 77 145 ± 32
PSBP (mmHg)
HPC (236 mg CGA) 129 ± 4 128 ± 3 130 ± 3 128 ± 2
LPC (108 mg CGA) 126 ± 2 127 ± 2 128 ± 2 132 ± 3
Control (0 g CGA) 126 ± 3 132 ± 2 125 ± 2 129 ± 3
PDBP (mmHg)
HPC (236 mg CGA) 70 ± 3 75 ± 2 74 ± 2 75 ± 2
LPC (108 mg CGA) 72 ± 2 79 ± 2 73 ± 1 75 ± 2
Control (0 g CGA) 70 ± 2 79 ± 2 74 ± 2 74 ± 2
PSBP, peripheral systolic blood pressure; PDBP, peripheral diastolic blood pressure;
IAUC SNP (PU.h1), incremental area under the curve of ﬂux vs. time for endothe-
lium independent micro vascular dilation (using sodium nitroprusside) as measured
by laser Doppler imaging; IAUC Ach (PU.h1) of ﬂux vs. time for endothelium
dependent micro vascular dilation (using acetylcholine) as measured by laser
Doppler imaging; HPC, high polyphenol coffee; LPC, low polyphenol coffee.
a Values are expressed as means ± SEM (n ¼ 15). No signiﬁcant differences were
found between baseline and post intervention (1, 3 and 5 h) or between control and
coffee treatments (p > 0.05).
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plasma post intervention for HPC, LPC and control (Supplementary
Table 2, 3 and 4 respectively). Both LPC and HPC induced an in-
crease in 13 metabolites; 3-caffeoylquinic acid (3CQA), 4-
caffeoylquinic acid (4CQA), caffeic-40-O-sulfate (CA4S), 3-
feruloylquinic acid (3FQA), 4-feruloylquinic acid (4FQA), 5-
feruloylquinic acid (5FQA), ferulic acid (FA), isoferulic acid (iFA),
methylferulic acid (MeFA), ferulic-40-O-glucuronide (F4G), iso-
ferulic-30-O-glucuronide (iF3G), ferulic-40-O-sulfate (F4S), and iso-
ferulic-30-O-sulfate (iF4S) (p < 0.001e0.05) relative to the control at
1 h post interventions (Fig. 3, AeM). At 5 h post intervention, only
four metabolites; caffeic-30-O-sulfate (CA3S), MeFA, F4S and iF3G
increased relative to the control (p < 0.001e0.05) (Fig. 3, C, I and L).
3.4. Plasma metabolite changes predict changes in FMD
A signiﬁcant, positive correlation was observed between total
plasma CGA metabolites and % FMD across the whole study period
(r ¼ 0.21, p ¼ 0.005; Pearson correlation). Furthermore, Pearson
correlation assessments for individual metabolites (HPC and LCP
combined) can be seen in Supplementary Table 5. Over the 0e1 h
time frame, positive correlations (r > 0.2) were observed between %
FMD and 3-CQA, 4-CQA, caffeic-30-O-sulfate (C3S), 5-FQA, iF3G and
F4S, which were signiﬁcant for 3-CQA, 4-CQA, C3S and 5-FQA
(p < 0.05), suggesting that these metabolites may be, at least in
part, involved in mediating the observed increases in endothelium-Table 5
Acute effects of chlorogenic acid on blood pressure.
Baseline 0.5 h 1
PSBP (mmHg)
0 mg CGA 119.9 ± 1.2 119.9 ± 1.5 11
450 mg CGA 118.5 ± 1.4 118.4 ± 1.6 11
900 mg CGA 119.6 ± 1.4 117.9 ± 1.5 11
200 mg ()-epicatechin 118.4 ± 1.9 118.6 ± 1.6 11
PDBP (mmHg)
0 mg CGA 65.0 ± 1.2 65.2 ± 1.2 65
450 mg CGA 65.6 ± 1.2 65.4 ± 1.2 64
900 mg CGA 65.8 ± 1.2 66.1 ± 1.3 67
200 mg ()-epicatechin 63.5 ± 1.3 63.5 ± 1.3 64
PSBP (peripheral systolic blood pressure) and PDBP (peripheral diastolic blood pressure)dependent vascular function between 0 and 1 h. When the same
analysis was conducted for the 3e5 h period (representing the
second peak in % FMD), positive correlations (r > 0.2) were seen
with C4S, isoferulic-30-O-glucuronide (iF3G), F4S, m-coumaric acid-
30-O-sulfate (mCo3S) and 4-methoxycinnamic acid (4MeCinA), all
were signiﬁcant (p < 0.05) (Supplementary Table 5). This suggests
that these metabolites may predict the magnitude of FMD increase
over this time frame.
3.5. FMD in response to pure CGA administration
As clinical efﬁcacy study indicated a relationship between total
circulating CGA metabolites and % FMD response in individuals, we
conducted a proof of concept study to test the efﬁcacy of pure 5-CQA
(450 mg and 900 mg) administration, alongside a control and pos-
itive control (epicatechin [27]) on human vascular function. One
hour after the oral ingestion of 5-CQA, the 450 mg dose, increased
FMD in all volunteers to a magnitude that almost achieved signiﬁ-
cance in comparison to the control (6.02 ± 0.28% to 6.77 ± 0.42%,
p¼ 0.06), whereas intake of the water control or the higher 900mg
dose of 5-CQA had no effect on % FMD (5.90 ± 0.33% to 5.86 ± 0.30%
and 6.17 ± 0.31% to 6.46 ± 0.35%, respectively) (Fig. 4, A). Four hours
after the ingestion of the treatments, values of FMDwere6.11±0.3%,
6.83±0.34% (p¼0.08) and6.34±0.34% forwater, 450 and900mgof
CQA. The positive control, ()-epicatechin, which has been previ-
ously reported to induce increased vascular function (assessed by
FMD) [27], induced a signiﬁcant increase in % FMD at 1 h. Total
plasma CGA metabolites post intervention of 450 mg of CGA were
lower than following intake of the 900 mg dose, but both signiﬁ-
cantly increased (p ¼ 0.032 and p ¼ 0.006 respectively) (Fig. 4, B).
4. Discussion
A bi-phasic increase in FMDwith peaks at 1 and 5 hwas observed
post consumption of HPC and LPC, which was accompanied by
concomitant increases in plasma levels of CGAmetabolites. At both 1
and 5 h post intervention, therewas a signiﬁcant increase in brachial
artery dilatation in comparison to the control drink after consump-
tion of theHPC (p<0.01 andp< 0.001 respectively) andwith the LPC
(p< 0.05 and 0.05 respectively). Previouswork focusing on the effect
of coffee on vascular health has predominantly centered on the
physiological actions of caffeine and have not been controlled for
phenolic content, leading tomixed results with respect to vasoactive
efﬁcacy [8,28]. In agreement with our data, an intake-dependence
investigation using decaffeinated coffee indicated that higher levels
of intake resulted in increases % FMD suggesting that compounds
other than caffeine, likely CGA and related phenolics may contribute
to vascular function [29]. In contrast to our data which used 5-CQA
(the most abundant CGA in coffee), previous studies with pure 3-
CQA showed no efﬁcacy towards FMD [30]. Our study provides
further evidence for the potential beneﬁcial effects of low/moderateh 2 h 3 h 4 h
8.6 ± 1.4 117.9 ± 1.2 117.0 ± 0.9 121.3 ± 0.9
6.8 ± 1.6 117.3 ± 1.2 116.7 ± 1.2 118.4 ± 1.2
9.8 ± 1.7 117.1 ± 1.7 117.8 ± 1.7 120.0 ± 1.7
8.2 ± 1.5 120.1 ± 1.9 117.0 ± 1.8 117.0 ± 1.8
.8 ± 0.9 66.0 ± 0.9 65.8 ± 1.1 67.0 ± 1.1
.6 ± 1.3 64.3 ± 1.0 65.5 ± 1.0 66.0 ± 1.0
.6 ± 0.8 65.6 ± 1.0 65.3 ± 0.9 66.1 ± 1.1
.8 ± 1.2 67.0 ± 1.4 65.5 ± 1.2 66.2 ± 1.0
.
Fig. 3. Potential drivers of FMD response at 1 and5 h asmean (±SEM) plasma concentrations of (A, 3-caffeoylquinic acid), (B, 4-caffeoylquinic acid), (C, caffeic-30-O-sulfate), (D, caffeic-40-
O-sulfate), (E, 3- feruloylquinic acid), (F, 4- feruloylquinic), (G, ferulic acid), (H, isoferulic acid), (I, methylferulic acid), (J, ferulic-40-O-glucuronide), (K, isoferulic-30-O-glurcuronide), (L,
ferulic-40-O-sulfate), (M, isoferulic-30-O-sulfate) after consumption of high polyphenol 310mg ( ) or low polyphenol 89mg ( ) coffees or control ( ) (n¼ 15). Datawere analyzed
using a 2- factor repeatedmeasures AVOVAwith time and treatment as the two factors [signiﬁcant effect of time (p < 0.05), treatment (p < 0.001)]. Post hoc analyses were conducted by
using Tukey's multiple comparisons test. Plasma concentrations signiﬁcantly different compared with the control drink at the speciﬁed time point: *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 4. Change in % FMD (A) and chlorogenic acid metabolites (B) 1 h post ingestion of
0 mg, 450 mg or 900 mg 5-caffeoylquinic acid (B) and 450 mg ()-epicatechin (A)
(n ¼ 24). Data were analyzed using two-way repeated measures ANOVA with time and
treatment as the two factors. Post hoc analyses were conducted using a Tukey's HSD
multiple comparisons test. Values presented are means ± SEM. *p < 0.05, **p < 0.01.
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ﬁrst time, into the temporal nature of its vasoactive beneﬁts post
intake, how efﬁcacy is affected by the dose of phenolics delivered in
the coffee and insights into the potential circulatingmetabolites that
might mediate such effects.
As direct cause-and-effect relationships between intake and
efﬁcacy are difﬁcult to establish following the intake of complex
foodmatrices such as coffee, we performed a proof of concept study
with puriﬁed 5-CQA. Data indicated that pure 5-CQA intake im-
proves vascular function but only at the 450mg and not the 900mg
intake level, something previously observed following the intake of
ﬂavonoid-rich foods/beverages [31], suggesting that there is anoptimal level of circulating polyphenol metabolites for driving
physiological effects on the endothelium. In support of this ﬁnding,
observational studies suggest that moderate coffee intake (4 cups),
equating to anywhere between about 105 and 500 mg of CGA
(depending on the processing conditions such as roasting), is
associated with lower cardiovascular disease risk [1,2]. Combining
datasets, illustrates a potentially Gaussian nature to the dose-
dependency of CGA on vascular function, with 89 and 310 mg
(delivered via coffee and caffeine matched) increasing blood ﬂow
by 1.1 and 1.34% FMD, respectively, whilst the 450 mg and 900 mg
(pure), resulting in 0.75 and 0.28% FMD, respectively.
In order to investigate the metabolite(s) mediating these in vivo
effects, we assessed the pharmacokinetic proﬁle of circulating CGA
metabolites up to 5 h post intake. Such data are scarce, with a
number of studies conducted in rats [32e35] and others only
reporting measurement of a limited numbers of plasma metabo-
lites [36e38]. Our data suggest positive correlations between
circulating levels of 3-CQA, 4-CQA and 5-FQA and the sulfate/
glucuronide metabolites, C3S, F4S and iF3G (p < 0.05). C3S was the
only metabolite that correlated, but had not signiﬁcantly increased
from baseline to 1 h (all others had p < 0.05); suggesting that it is
not an important compound with regards to driving the ﬁrst FMD
peak (1 h). Whilst between 3 and 5 h positive correlations were
observed for C4S, iF3G, F4S, mCo3S and 4MeCinA (p < 0.05), with
F4S and iF3G appearing to mediate vascular efﬁcacy at the second
peak (5 h). The nature of these metabolites, along with the detec-
tion of un-metabolized CGA in plasma is consistent with previous
investigations [37e39], with phenolic acid sulfates, which have
previously been shown to reach Cmax at approximately 1 h after
coffee ingestion [40]. Potential mechanisms by which such circu-
lating metabolites mediate their vascular effects have been postu-
lated, and include their potential to inhibit NAPDH oxidase, thus
affecting superoxide production and subsequent NO bioavailability
at the vascular epithelium [31,41e43]. Notably, CGA administration
to spontaneously hypertensive rats improves endothelium depen-
dent vasodilation and decreases blood pressure via effects on
NADPH oxidase activity and by increasing NO production [44].
Structural similarities between speciﬁc circulating CGA-derived
metabolites and apocynin [45] (namely due to ferulic and caffeic
acid moieties) provide support for such as mechanism, although
direct inhibition of NADPH oxidase was not assessed in the current
studies.
We acknowledge limitations within our studies and appreciate
the difﬁculty in establishing causeeeffect relationships. We
recognize that in intervention efﬁcacy study the control drink was
not matched for macro and micro nutrients, and therefore the FMD
response could well be due to the response to other compounds
present in the coffee drinks and not in the control.
Further, both studies are short acute investigations which show
the effect of coffee up to ﬁve hours after consumption and cannot
be used to determine the long term effects of repeated consump-
tion of coffee on vascular function. In addition, the study population
was limited to healthy, young male participants and cannot be
directly used to predict the vascular response that would be
observed in other populations, for example females, elderly or
those at risk for cardiovascular disease.
Our data, emanating from the two clinical trials, suggest that the
acute increases in endothelium-dependent dilation following
either coffee, or pure CGA may reﬂect the potential of phenolic
metabolites to inﬂuence the bioavailability of nitric oxide within
the vasculature. The vasoactive effects of coffee consumption are
evident at moderate levels of consumption, with efﬁcacy following
a Gaussian proﬁle with respect to total phenolic intake (at least at
1 h post intake). These data provide an insight into the potential
beneﬁcial vascular effects of coffee intake, although longer-term
C.E. Mills et al. / Clinical Nutrition 36 (2017) 1520e15291528interventions are required to assess whether these acute effects
may be sustained over time, following repeated consumption of
different types of coffee.
Conﬂict of interest
Authors LAG, DZ, CM and LP are, at the time of submission of this
manuscript, employees of Nestec Ltd, which is a subsidiary of
Nestle Ltd. and provide professional assistance, research, and
consulting services for food, dietary, dietetic, and pharmaceutical
products of interest to Nestle Ltd. No other conﬂicts of interest were
reported.
Acknowledgments
JPESwas the PI on the study, GRG and DMwere co-PI's andMJOC
was a postdoctoral researcher assigned to the project. JPES, MJOC
and CEM designed the efﬁcacy study protocol and LAG and DZ
designed the POC study protocol. CEM coordinated and conducted
the efﬁcacy study. AF, SR, CS, ER, RB and YA coordinated and con-
ducted the POC study; CM and LP carried out the metabolite anal-
ysis. JPES, LAG and CEM collaborated on the manuscript
preparation. All authors read and approved the ﬁnal manuscript.
We thank Celine Romagny, Marianne Mori and Elisa Bouillet for
their help in the clinical POC study.
This work was supported ﬁnancially by the Biotechnology and
Biological Sciences Research Council Diet and Health Research In-
dustry Club (BBSRC DRINC; BB/G005702/1). Nestec Ltd, a subsidiary
of Nestle Ltd, also contributed to the study through the BBSRC
DRINC, by supplying interventions.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.clnu.2016.11.013.
References
[1] Kim B, Nam Y, Kim J, Choi H, Won C. Coffee consumption and stroke risk: a
meta-analysis of epidemiologic studies. Korean J Fam Med 2012;33(6):
356e65.
[2] Mostofsky E, Rice MS, Levitan EB, Mittleman MA. Habitual coffee consumption
and risk of heart failure: a dose-response meta-analysis. Circ Heart Fail
2012;5(4):401e5.
[3] Mills CE, Oruna-Concha MJ, Mottram DS, Gibson GR, Spencer JPE. The effect of
processing on chlorogenic acid content of commercially available coffee. Food
Chem 2013;141(4):3335e40.
[4] Neto CC. Cranberry and blueberry: evidence for protective effects against
cancer and vascular diseases. Mol Nutr Food Res 2007;51(6):652e64.
[5] Vauzour D, Houseman EJ, George TW, Corona G, Garnotel R, Jackson KG, et al.
Moderate Champagne consumption promotes an acute improvement in acute
endothelial-independent vascular function in healthy human volunteers. Br J
Nutr 2010;103(8):1168e78.
[6] Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, et al. Cocoa
reduces blood pressure and insulin resistance and improves endothelium-
dependent vasodilation in hypertensives. Hypertension 2005;46(2):398e405.
[8] Papamichael CM, Aznaouridis KA, Karatzis EN, Karatzi KN,
Stamatelopoulos KS, Vamvakou G, et al. Effect of coffee on endothelial func-
tion in healthy subjects: the role of caffeine. Clin Sci 2005;109(1):55e60.
[9] Mahmud A, Feely J. Acute effect of caffeine on arterial stiffness and aortic
pressure waveform. Hypertension 2001;38(2):227e31.
[10] Umemura T, Ueda K, Nishioka K, Hidaka T, Takemoto H, Nakamura S, et al.
Effects of acute administration of caffeine on vascular function. Am J Cardiol
2006;98(11):1538e41.
[11] Watanabe T, Arai Y, Mitsui Y, Kusaura T, Okawa W, Kajihara Y, et al. The blood
pressure-lowering effect and safety of chlorogenic acid from green coffee
bean extract in essential hypertension. Clin Exp Hypertens 2006;28(5):
439e49.
[12] Suzuki A, Yamamoto N, Jokura H, Yamamoto M, Fujii A, Tokimitsu I, et al.
Chlorogenic acid attenuates hypertension and improves endothelial function
in spontaneously hypertensive rats. J Hypertens 2006;24(6):1075e82. http://
dx.doi.org/10.1097/01.hjh.0000226196.67052.c0.[13] Rodriguez de Sotillo DV, Hadley M. Chlorogenic acid modiﬁes plasma and liver
concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker
rats. J Nutr Biochem 2002;13(12):717e26.
[14] Ochiai R, Sugiura Y, Shioya Y, Otsuka K, Katsuragi Y, Hashiguchi T. Coffee
polyphenols improve peripheral endothelial function after glucose loading in
healthy male adults. Nutr Res 2014;34(2):155e9.
[15] Ochiai R, Sugiura Y, Otsuka K, Katsuragi Y, Hashiguchi T. Coffee bean poly-
phenols ameliorate postprandial endothelial dysfunction in healthy male
adults. Int J Food Sci Nutr 2015;66(3):350e4.
[16] Moon JK, Yoo HS, Shibamoto T. Role of roasting conditions in the level of
chlorogenic acid content in coffee beans: correlation with coffee acidity.
J Agric Food Chem 2009;57(12):5365e9.
[17] Olthof MR, Hollman PC, Katan MB. Chlorogenic acid and caffeic acid are
absorbed in humans. J Nutr 2001;131(1):66e71.
[18] StalmachA,SteilingH,WilliamsonG,CrozierA.Bioavailabilityof chlorogenic acids
following acute ingestion of coffee by humans with an ileostomy. Arch Biochem
Biophys 2010;501(1):98e105.
[19] Gonthier M-P, Verny M-A, Besson C, Remesy C, Scalbert A. Chlorogenic acid
bioavailability largely depends on its metabolism by the gut microﬂora in rats.
J Nutr 2003;133(6):1853e9.
[20] Siddiqi N, Neil C, Bruce M, Maclennan G, Cotton S, Papadopoulou S, et al.
Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a
randomized controlled trial (NIAMI). Eur Heart J 2014;35(19):1255e62.
[21] Ding M, Bhupathiraju SN, Satija A, Van Dam RM, Hu FB. Long-term coffee
consumption and risk of cardiovascular disease: a systematic review and a
doseeresponse meta-analysis of prospective cohort studies. Circulation
2014;129(6):643e59.
[22] Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F,
Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-
dependent ﬂow-mediated vasodilation of the brachial artery: a report of
the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol
2002;39(2):257e65.
[23] Rimoldi SF, Ott S, Rexhaj E, De Marchi SF, Allemann Y, Gugger M, et al. Patent
foramen ovale closure in obstructive sleep apnea improves blood pressure
and cardiovascular function. Hypertension 2015;66(5):1050e7.
[24] George TW, Paterson E, Waroonphan S, Gordon MH, Lovegrove JA. Effects of
chronic consumption of fruit and vegetable puree-based drinks on vasodila-
tion, plasma oxidative stability and antioxidant status. J Hum Nutr Diet
2012;25(5):477e87.
[25] Marmet C, Actis-Goretta L, Renouf M, Giuffrida F. Quantiﬁcation of phenolic
acids and their methylates, glucuronides, sulfates and lactones metabolites in
human plasma by LCeMS/MS after oral ingestion of soluble coffee. J Pharm
Biomed Anal 2014;88(0):617e25.
[26] Heiss C, Kleinbongard P, Dejam A, Perre S, Schroeter H, Sies H, et al. Acute
consumption of ﬂavanol-rich cocoa and the reversal of endothelial dysfunc-
tion in smokers. J Am Coll Cardiol 2005;46(7):1276e83.
[27] Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al.
(-)-Epicatechin mediates beneﬁcial effects of ﬂavanol-rich cocoa on vascular
function in humans. Proc Natl Acad Sci U. S. A 2006;103(4):1024e9.
[28] Buscemi S, Batsis JA, Arcoleo G, Verga S. Acute effects of coffee on endothelial
function in healthy subjects 2010;64(5):483e9.
[29] Buscemi S, Verga S, Batsis JA, Donatelli M, Tranchina MR, Belmonte S, et al.
Coffee and endothelial function: a battle between caffeine and antioxidants
[quest]. Eur J Clin Nutr 2010;64(10):1242e3.
[30] Mubarak A, Bondonno CP, Liu AH, Considine MJ, Rich L, Mas E, et al. Acute
effects of chlorogenic acid on nitric oxide status, endothelial function and
blood pressure in healthy volunteers: a randomised trial. J Agric Food Chem
2012;60(36).
[31] Rodriguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George TW,
Heiss C, et al. Intake and time dependence of blueberry ﬂavonoideinduced
improvements in vascular function: a randomized, controlled, double-blind,
crossover intervention study with mechanistic insights into biological activ-
ity. Am J Clin Nutr 2013;98(5):1179e91.
[32] Lafay S, Gil-Izquierdo A, Manach C, Morand C, Besson C, Scalbert A. Chloro-
genic acid is absorbed in its intact form in the stomach of rats. J Nutr
2006;136(5):1192e7.
[33] Lafay S, Morand C, Manach C, Besson C, Scalbert A. Absorption and meta-
bolism of caffeic acid and chlorogenic acid in the small intestine of rats. Br J
Nutr 2006;96(1):39e46.
[34] Dupas C, Marsset Baglieri A, Ordonaud C, Tome D, Maillard MN. Chlorogenic
acid is poorly absorbed, independently of the food matrix: a Caco-2 cells and
rat chronic absorption study. Mol Nutr Food Res 2006;50(11):1053e60.
[35] Azuma K, Ippoushi K, Nakayama M, Ito H, Higashio H, Terao J. Absorption of
chlorogenic acid and caffeic acid in rats after oral administration. J Agric Food
Chem 2000;48(11):5496e500.
[36] Olthof MR, Hollman PCH, Buijsman MNCP, Van Amelsvoort JMM, Katan MB.
Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are exten-
sively metabolized in humans. J Nutr 2003;133(6):1806e14.
[37] Monteiro M, Farah A, Perrone D, Trugo LC, Donangelo C. Chlorogenic acid
compounds from coffee are differentially absorbed and metabolized in
humans. J Nutr 2007;137(10):2196e201.
[38] Nardini M, Cirillo E, Natella F, Scaccini C. Absorption of phenolic acids in
humans after coffee consumption. J Agric Food Chem 2002;50(20):5735e41.
[39] Farah A, Monteiro M, Donangelo CM, Lafay S. Chlorogenic acids from green
coffee extract are highly bioavailable in humans. J Nutr 2008;138(12):2309e15.
C.E. Mills et al. / Clinical Nutrition 36 (2017) 1520e1529 1529[40] Stalmach A, Mullen W, Barron D, Uchida K, Yokota T, Christophe C, et al.
Metabolite proﬁling of hydroxycinnammate derivatives in plasma and urine
after the ingestion of coffee by humans: identiﬁcation of biomarkers of coffee
consumption. Drug Metab Dispos 2009;37:1749e58.
[41] Schewe T, Steffen Y, Sies H. How do dietary ﬂavanols improve vascular
function? A position paper. Arch Biochem Biophys 2008;476(2):102e6.
[42] Steffen Y, Gruber C, Schewe T, Sies H. Mono-O-methylated ﬂavanols and other
ﬂavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys
2008;469(2):209e19.[43] Steffen Y, Schewe T, Sies H. (e)-Epicatechin elevates nitric oxide in endo-
thelial cells via inhibition of NADPH oxidase. Biochem Biophys Res Commun
2007;359(3):828e33.
[44] Suzuki A, Yamamoto N, Jokura H, Yamamoto M, Fujii A, Tokimitsu I, et al.
Chlorogenic acid attenuates hypertension and improves endothelial function
in spontaneously hypertensive rats. J Hypertens 2006;24(6):1065e73.
[45] Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhi-
bition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-
substituted catechol. Am J Respir Cell Mol Biol 1994;11(1):95e102.
